CAMBRIDGE, MA / ACCESS Newswire / March 31, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Australian Therapeutic Goods Administration (TGA) has granted approval for mRESVIA® (mRNA-1345), ...

The resignation of one of the FDA's top officials, Peter Marks, is worrying Wall Street as they await a replacement.

Moderna, Inc. (NASDAQ:MRNA) today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK has granted marketing authorization for mRESVIA (mRNA-1345), indicated for ...

The risk for new-onset or recurrent AF was not increased among older adult patients with preexisting conditions following RSV vaccination.

Stock futures edged lower on Monday due to trade war concerns and the upcoming 25% levy on non-US cars. President Trump has ...

Researchers at the University of Cologne have found that mRNA-based COVID-19 vaccines have a lasting impact on the innate ...

Total company revenue fell from a peak of $19.3 billion in 2022 to $3.2 billion for the full year ended Dec. 31, 2024. For ...

AIM Vaccine Co., Ltd. (06660.HK), a leading PRC vaccine company, published its 2024 Annual Results announcement on March 30, ...

An Australian-first study demonstrating the effectiveness of a new immunization against respiratory syncytial virus (RSV) for ...

In a recent final analysis of a phase 3 trial, the bivalent respiratory syncytial virus prefusion F (RSVpreF) vaccine maintained high efficacy and a favorable safety profile against RSV-associated ...

Researchers have discovered that mRNA-based COVID-19 vaccines have a persistent effect on the innate immune system. These mechanisms may help the human body to better protect itself against potential ...